Joel Beatty
Stock Analyst at Baird
(4.25)
# 484
Out of 4,732 analysts
182
Total ratings
42.47%
Success rate
19.27%
Average return
Main Sectors:
Stocks Rated by Joel Beatty
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DNLI Denali Therapeutics | Initiates: Outperform | $31 | $21.93 | +41.36% | 1 | Jan 7, 2025 | |
| EDIT Editas Medicine | Maintains: Outperform | $10 → $8 | $1.22 | +555.74% | 3 | Dec 13, 2024 | |
| PTCT PTC Therapeutics | Maintains: Outperform | $52 → $70 | $43.84 | +59.67% | 14 | Dec 3, 2024 | |
| DRUG Bright Minds Biosciences | Initiates: Outperform | $75 | $36.78 | +103.92% | 1 | Nov 25, 2024 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Outperform | $154 → $162 | $121.18 | +33.69% | 3 | Nov 18, 2024 | |
| AMLX Amylyx Pharmaceuticals | Upgrades: Outperform | $3 → $11 | $3.60 | +205.56% | 4 | Nov 18, 2024 | |
| IMMP Immutep | Maintains: Outperform | $6 → $7 | $1.93 | +262.69% | 5 | Nov 15, 2024 | |
| AXSM Axsome Therapeutics | Maintains: Outperform | $112 → $116 | $91.94 | +26.18% | 3 | Nov 13, 2024 | |
| NGNE Neurogene | Maintains: Outperform | $54 → $72 | $16.60 | +333.73% | 2 | Nov 12, 2024 | |
| ARGX argenx SE | Downgrades: Neutral | $515 → $650 | $640.52 | +1.48% | 5 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $72 → $65 | $61.53 | +5.64% | 5 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $32 | $12.44 | +157.23% | 1 | Oct 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $240 → $175 | $126.95 | +37.85% | 4 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $9 | $7.08 | +27.12% | 4 | Oct 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $8 → $10 | $8.03 | +24.53% | 3 | Sep 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $16 | $3.34 | +379.04% | 1 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $112 → $127 | $110.05 | +15.40% | 3 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $58 | $20.00 | +190.00% | 1 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $37 → $38 | $29.47 | +28.94% | 2 | Jul 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $72 | $40.00 | +80.00% | 4 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $27 | $7.16 | +277.36% | 1 | May 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $45 → $20 | $0.89 | +2,137.39% | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $28 | $17.57 | +59.36% | 3 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $117 | $70.54 | +65.86% | 1 | May 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $4.5 | $2.89 | +55.71% | 2 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $83 → $103 | $126.20 | -18.38% | 2 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $25 | $19.14 | +30.62% | 3 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $9 | $2.55 | +252.94% | 2 | Mar 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $28 | $13.08 | +114.07% | 2 | Oct 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $16 | $6.45 | +148.06% | 1 | Jun 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $3.55 | +97.18% | 1 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $1.25 | $1.72 | -27.33% | 2 | May 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $44 | $11.21 | +292.51% | 3 | Apr 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $60 → $58 | $19.56 | +196.52% | 6 | Feb 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $24 | $22.18 | +8.21% | 2 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $18 | $16.79 | +7.21% | 3 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $6 | $3.45 | +73.91% | 2 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $46 → $31 | $1.77 | +1,651.41% | 3 | Jun 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $36 → $28 | $10.11 | +176.95% | 2 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $170 → $175 | $246.27 | -28.94% | 2 | Feb 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $14 | $4.36 | +221.10% | 8 | Jan 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $108 | $118.00 | -8.47% | 10 | Jan 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 → $78 | $31.43 | +148.17% | 3 | Aug 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $140 → $100 | $4.47 | +2,139.64% | 2 | Apr 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $24 → $6 | $0.56 | +975.27% | 14 | Apr 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $15 | $0.51 | +2,855.08% | 2 | Mar 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $2.21 | - | 12 | Mar 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $15 | $8.40 | +78.57% | 11 | Sep 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $240 → $120 | $1.51 | +7,847.02% | 2 | Aug 17, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $19 | $7.26 | +161.71% | 3 | Nov 10, 2017 |
Denali Therapeutics
Jan 7, 2025
Initiates: Outperform
Price Target: $31
Current: $21.93
Upside: +41.36%
Editas Medicine
Dec 13, 2024
Maintains: Outperform
Price Target: $10 → $8
Current: $1.22
Upside: +555.74%
PTC Therapeutics
Dec 3, 2024
Maintains: Outperform
Price Target: $52 → $70
Current: $43.84
Upside: +59.67%
Bright Minds Biosciences
Nov 25, 2024
Initiates: Outperform
Price Target: $75
Current: $36.78
Upside: +103.92%
Jazz Pharmaceuticals
Nov 18, 2024
Maintains: Outperform
Price Target: $154 → $162
Current: $121.18
Upside: +33.69%
Amylyx Pharmaceuticals
Nov 18, 2024
Upgrades: Outperform
Price Target: $3 → $11
Current: $3.60
Upside: +205.56%
Immutep
Nov 15, 2024
Maintains: Outperform
Price Target: $6 → $7
Current: $1.93
Upside: +262.69%
Axsome Therapeutics
Nov 13, 2024
Maintains: Outperform
Price Target: $112 → $116
Current: $91.94
Upside: +26.18%
Neurogene
Nov 12, 2024
Maintains: Outperform
Price Target: $54 → $72
Current: $16.60
Upside: +333.73%
argenx SE
Nov 1, 2024
Downgrades: Neutral
Price Target: $515 → $650
Current: $640.52
Upside: +1.48%
Oct 30, 2024
Maintains: Neutral
Price Target: $72 → $65
Current: $61.53
Upside: +5.64%
Oct 22, 2024
Initiates: Outperform
Price Target: $32
Current: $12.44
Upside: +157.23%
Oct 21, 2024
Maintains: Outperform
Price Target: $240 → $175
Current: $126.95
Upside: +37.85%
Oct 9, 2024
Maintains: Neutral
Price Target: $13 → $9
Current: $7.08
Upside: +27.12%
Sep 5, 2024
Maintains: Neutral
Price Target: $8 → $10
Current: $8.03
Upside: +24.53%
Sep 4, 2024
Initiates: Outperform
Price Target: $16
Current: $3.34
Upside: +379.04%
Aug 2, 2024
Maintains: Outperform
Price Target: $112 → $127
Current: $110.05
Upside: +15.40%
Jul 26, 2024
Initiates: Outperform
Price Target: $58
Current: $20.00
Upside: +190.00%
Jul 25, 2024
Maintains: Outperform
Price Target: $37 → $38
Current: $29.47
Upside: +28.94%
May 31, 2024
Maintains: Outperform
Price Target: $68 → $72
Current: $40.00
Upside: +80.00%
May 28, 2024
Initiates: Outperform
Price Target: $27
Current: $7.16
Upside: +277.36%
May 15, 2024
Maintains: Outperform
Price Target: $45 → $20
Current: $0.89
Upside: +2,137.39%
May 9, 2024
Maintains: Outperform
Price Target: $31 → $28
Current: $17.57
Upside: +59.36%
May 1, 2024
Initiates: Outperform
Price Target: $117
Current: $70.54
Upside: +65.86%
Apr 30, 2024
Downgrades: Neutral
Price Target: $4.5
Current: $2.89
Upside: +55.71%
Apr 17, 2024
Maintains: Outperform
Price Target: $83 → $103
Current: $126.20
Upside: -18.38%
Apr 11, 2024
Maintains: Outperform
Price Target: $24 → $25
Current: $19.14
Upside: +30.62%
Mar 19, 2024
Maintains: Outperform
Price Target: $11 → $9
Current: $2.55
Upside: +252.94%
Oct 3, 2023
Maintains: Outperform
Price Target: $32 → $28
Current: $13.08
Upside: +114.07%
Jun 1, 2023
Initiates: Outperform
Price Target: $16
Current: $6.45
Upside: +148.06%
May 23, 2023
Initiates: Outperform
Price Target: $7
Current: $3.55
Upside: +97.18%
May 2, 2023
Maintains: Outperform
Price Target: $4 → $1.25
Current: $1.72
Upside: -27.33%
Apr 13, 2023
Initiates: Outperform
Price Target: $44
Current: $11.21
Upside: +292.51%
Feb 7, 2023
Maintains: Outperform
Price Target: $60 → $58
Current: $19.56
Upside: +196.52%
Nov 18, 2022
Maintains: Outperform
Price Target: $18 → $24
Current: $22.18
Upside: +8.21%
Nov 10, 2022
Downgrades: Underperform
Price Target: $18
Current: $16.79
Upside: +7.21%
Aug 29, 2022
Maintains: Outperform
Price Target: $9 → $6
Current: $3.45
Upside: +73.91%
Jun 1, 2022
Maintains: Outperform
Price Target: $46 → $31
Current: $1.77
Upside: +1,651.41%
Mar 3, 2022
Upgrades: Neutral
Price Target: $36 → $28
Current: $10.11
Upside: +176.95%
Feb 12, 2021
Downgrades: Neutral
Price Target: $170 → $175
Current: $246.27
Upside: -28.94%
Jan 14, 2021
Downgrades: Neutral
Price Target: $14
Current: $4.36
Upside: +221.10%
Jan 12, 2021
Downgrades: Neutral
Price Target: $108
Current: $118.00
Upside: -8.47%
Aug 10, 2020
Maintains: Buy
Price Target: $80 → $78
Current: $31.43
Upside: +148.17%
Apr 6, 2020
Maintains: Buy
Price Target: $140 → $100
Current: $4.47
Upside: +2,139.64%
Apr 1, 2020
Maintains: Buy
Price Target: $24 → $6
Current: $0.56
Upside: +975.27%
Mar 26, 2020
Maintains: Buy
Price Target: $16 → $15
Current: $0.51
Upside: +2,855.08%
Mar 17, 2020
Upgrades: Buy
Price Target: n/a
Current: $2.21
Upside: -
Sep 24, 2019
Maintains: Buy
Price Target: $19 → $15
Current: $8.40
Upside: +78.57%
Aug 17, 2018
Maintains: Neutral
Price Target: $240 → $120
Current: $1.51
Upside: +7,847.02%
Nov 10, 2017
Maintains: Buy
Price Target: $15 → $19
Current: $7.26
Upside: +161.71%